ARTICLE | Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

January 22, 2015 8:00 AM UTC

Mouse studies suggest a brain-penetrating pan-EGFR inhibitor could help treat EGFR-expressing glioblastomas. In a mouse model of intracranial glioblastoma, the pan-EGFR inhibitor NT-113 delayed tumor growth and prolonged survival compared with EGFR1 inhibitor erlotinib or dual EGFR1 and HER2 inhibitor lapatinib. In the model, NT-113 exhibited anti-tumor activity against a broader range of tumors and had significantly higher brain-to-plasma and intracranial tumor-to-plasma ratios than erlotinib. Next steps include Phase I testing of NT-113 in glioblastoma and EGFR-positive solid tumors that metastasize to the brain.

NewGen Therapeutics Inc. and Kanion Pharmaceutical Co. Ltd. have NT-113 in preclinical testing to treat glioblastoma and other cancers...